Biodesix, Inc.
General ticker "BDSX" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $91.4M (TTM average)
Biodesix, Inc. does not follow the US Stock Market performance with the rate: -10.0%.
Estimated limits based on current volatility of 5.7%: low 14.59$, high 16.35$
Factors to consider:
- Total employees count: 273 (+25.8%) as of 2024
- Top business risk factors: Net losses and future profitability, Market acceptance of diagnostic tests, Third-party risks, Climate change and natural disasters, Regulatory and compliance
- Current price 18.2% above estimated high
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.37$, 13.42$]
- 2026-12-31 to 2027-12-31 estimated range: [3.70$, 11.60$]
Financial Metrics affecting the BDSX estimates:
- Negative: with PPE of -2.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -44.72 <= 0.01
- Negative: Shareholder equity ratio, % of -2.82 <= 19.40
- Negative: negative Net income
- Positive: Inventory ratio change, % of -0.13 <= 0
Short-term BDSX quotes
Long-term BDSX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $49.09MM | $71.32MM | $88.50MM |
| Operating Expenses | $90.43MM | $105.82MM | $116.37MM |
| Operating Income | $-41.34MM | $-34.50MM | $-27.87MM |
| Non-Operating Income | $-10.80MM | $-8.43MM | $-7.39MM |
| Interest Expense | $9.54MM | $8.26MM | $7.72MM |
| R&D Expense | $9.99MM | $9.56MM | $12.00MM |
| Income(Loss) | $-52.15MM | $-42.93MM | $-35.27MM |
| Profit(Loss)* | $-52.15MM | $-42.93MM | $-35.27MM |
| Stockholders Equity | $4.58MM | $20.88MM | $-2.46MM |
| Inventory | $1.40MM | $0.00MM | $0.00MM |
| Assets | $99.10MM | $97.24MM | $87.48MM |
| Operating Cash Flow | $-22.87MM | $-48.65MM | $-23.27MM |
| Capital expenditure | $23.06MM | $3.23MM | $0.26MM |
| Investing Cash Flow | $-23.06MM | $-3.44MM | $-0.40MM |
| Financing Cash Flow | $29.13MM | $52.05MM | $16.42MM |
| Earnings Per Share** | $-12.70 | $-6.62 | $-4.67 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.